577 nm阈值下微脉冲激光联合抗VEGF药物治疗难治性糖尿病性黄斑水肿的疗效观察

doi:10.6040/j.issn.1673-3770.0.2023.313

摘要/Abstract

摘要： 目的探讨577 nm阈值下微脉冲激光(subthrehold micropulse laser photocoagulation, SMLP)联合玻璃体腔注射康柏西普(intravitreal conbercept, IVC)与单纯IVC治疗难治性糖尿病性黄斑水肿(diabetic macular edema, DME)的临床疗效。方法本研究为非随机对照研究。选取2022年1月至2022年12月在湖南省人民医院眼科就诊的难治性DME患者,将入选病例分为实验组(共10例,16眼)和对照组(共12例,17眼)。实验组采用577 nm SMLP联合IVC治疗,对照组采用单纯IVC治疗。收集两组治疗基线及随访6个月每月的最佳矫正视力(best corrected visual acuity, BCVA)、黄斑中心视网膜厚度(central macular thickness, CMT)、硬性渗出面积(hard exudates, HE)及微血管瘤数量(microangioma, MA)的变化情况以及玻璃体腔注药次数,观察两组患者治疗后并发症的发生情况。结果治疗6个月后,实验组、对照组LogMAR BCVA分别为0.300(0.100,0.400)、0.400(0.300,0.600),两者差异具有统计学意义(t=-2.575,P=0.015);CMT分别为237.00(230.75,254.75)μm、263.00(237.00,341.50)μm,两者差异具有统计学意义(t=-2.252,P=0.035);HE［411.50(72.25, 8 757.50)pixels²］ vs. ［3 000.00(10.00,6 604.00)pixels² ］和MA［1.00(0.00,7.25)个］vs.［2.00(1.00,8.00)个］差异均无统计学意义(t=0.766, P=0.452; t=-0.861, P=0.400)。实验组、对照组的注药次数分别为(4.6±0.2)次、(5.3±0.2)次,差异具有统计学意义(t=-2.182,P=0.039)。实验组577 nm SMLP治疗6个月后患眼眼底检查无明显色素沉积和激光瘢痕。实验组与对照组在治疗6个月后均未见明显并发症发生。结论 577 nm SMLP具有较好的安全性。577 nm SMLP联合IVC与单纯IVC治疗对比,在针对难治性DME患者的HE面积和出血点、MA的数量改善方面具有同等的效果,但联合治疗能在短期内更好地减轻部分患者的黄斑水肿,提升BCVA,并且延长玻璃体腔注药间隔时间,减少玻璃体腔注药频次,具有一定的临床应用前景。

关键词: 阈值下微脉冲激光, 糖尿病性黄斑水肿, 康柏西普, 疗效观察

Abstract: Objective We compared the clinical efficacy of subthreshold micropulse laser photocoagulation(SMLP)with a threshold of 577 nm, combined with intravitreal injection of compacept(intravitreal conbercept, IVC), with that of IVC alone in the treatment of refractory diabetic macular edema(DME). Methods We designed and performed a non-randomized controlled study. Patients with refractory DME who were admitted to the Department of Ophthalmology, Hunan Provincial People's Hospital from January 2022 to December 2022 were selected and divided into an experimental group(10 cases, 16 eyes)and a control group(12 cases, 17 eyes). The experimental group received 577 nm SMLP combined with IVC treatment, and the control group received IVC alone. The changes in best corrected visual acuity(BCVA), central macular retinal thickness(CMT), hard exudates(HE)area, microangioma(MA), and the number of intravitreal injections were collected after 6 months of treatment in the two groups. The incidence of complications was recorded after treatment. Results After 6 months of treatment, the respective Log MAR BCVA values in the experimental and control groups were 0.300(0.100, 0.400)and 0.400(0.300, 0.600), respectively. The difference between these two groups was statistically significant(t=-2.575, P=0.015). The respective CMT values were 237.00(230.75, 254.75)μm and 263.00(237.00, 341.50)μm, and the difference was statistically significant(t=-2.252, P=0.035). No significant difference was observed between HE ［411.50(72.25, 8 757.50)pixels²］ vs. ［3 000.00(10.00, 6 604.00)pixels²］ and MA ［1.00(0.00, 7.25)vs.(4.55±4.78)］(t=0.766, P=0.452; t=-0.861, P=0.400). The numbers of injections in the experimental and control groups were(4.6±0.2)and(5.3±0.2), respectively. This difference was statistically significant(t=-2.182, P=0.039). After 6 months of treatment, no obvious pigment deposition or sign of laser scar was observed in the fundus examination of the affected eyes in the experimental group. No obvious complications were observed in the experimental group or the control group after 6 months of treatment. Conclusion SMLP at 577 nm demonstrated good safety. Compared with simple IVC treatment, 577 nm SMLP combined with IVC treatment improves HE area, number of bleeding points, and MA with the same efficacy in patients with refractory DME. However, combined treatment can better reduce macular edema in some patients in the short term, improve BCVA, prolong the interval of intravitreal injection, and reduce the frequency of intravitreal injection, offering promising prospects for clinical application.

Key words: Subthreshold micropulse laser photocoagulation, Diabetic macular edema, Conbercept, Effect observation

中图分类号:

R774.1

周静琳,李金香,曾琦. 577 nm阈值下微脉冲激光联合抗VEGF药物治疗难治性糖尿病性黄斑水肿的疗效观察[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 18-25.

ZHOU Jinglin, LI Jinxiang, ZENG Qi. Effect of 577 nm subthreshold micropulse laser photocoagulation combined with anti-VEGF on the treatment of refractory diabetic macular edema[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(2): 18-25.

参考文献 24

[1]	王娇娇, 李苗, 宋宗明. 糖尿病视网膜病变的机制和细胞模型研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 93-99. doi:10.6040/j.issn.1673-3770.0.2021.203 WANG Jiaojiao, LI Miao, SONG Zongming. Progress in diabetic retinopathy mechanisms and cellular models[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(5): 93-99. doi:10.6040/j.issn.1673-3770.0.2021.203
[2]	Chauhan MZ, Rather PA, Samarah SM, et al. Current and novel therapeutic approaches for treatment of diabetic macular edema[J]. Cells, 2022, 11(12): 1950. doi:10.3390/cells11121950
[3]	Kim EJ, Lin WV, Rodriguez SM, et al. Treatment of diabetic macular edema[J]. Curr Diab Rep, 2019, 19(9): 68. doi:10.1007/s11892-019-1188-4
[4]	赵子君, 柯晓云. 糖尿病性黄斑水肿治疗方式的研究进展[J]. 眼科新进展, 2019, 39(6): 596-600. doi:10.13389/j.cnki.rao.2019.0138 ZHAO Zijun, KE Xiaoyun. Recent advances in new emerging therapies of diabetic macular edema[J]. Recent Advances in Ophthalmology, 2019, 39(6): 596-600. doi:10.13389/j.cnki.rao.2019.0138
[5]	Chatziralli I, Loewenstein A. Intravitreal anti-vascular endothelial growth factor agents for the treatment of diabetic retinopathy: a review of the literature[J]. Pharmaceutics, 2021, 13(8): 1137. doi:10.3390/pharmaceutics13081137
[6]	Madjedi K, Pereira A, Ballios BG, et al. Switching between anti-VEGF agents in the management of refractory diabetic macular edema: a systematic review[J]. Surv Ophthalmol, 2022, 67(5): 1364-1372. doi:10.1016/j.survophthal.2022.04.001
[7]	张祺, 段淯平, 陈建斌. 阿柏西普联合阈值下微脉冲激光治疗糖尿病黄斑水肿[J]. 中国激光医学杂志, 2021, 30(1): 44. doi: 10.3870/j.issn.1004-0781.2021.05.010 ZHANG Qi, DUAN Yuping, CHEN Jianbin. Treatment of diabetic macular edema with arbasip combined with subthreshold micropulse laser[J]. Chinese Journal of Laser Medicine & Surgery, 2021, 30(1): 44. doi: 10.3870/j.issn.1004-0781.2021.05.010
[8]	Wu J, Yang K, Fan H, et al. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus[J]. Front Endocrinol(Lausanne), 2023, 14: 1114424. doi: 10.3389/fendo.2023.1114424
[9]	Hussain RM, Ciulla TA. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy[J]. Expert Opin Biol Ther, 2016, 16(3): 365-74. doi: 10.1517/14712598.2016.1131265
[10]	El Rami H, Barham R, Sun JK, et al. Evidence-based treatment of diabetic retinopathy[J]. emin Ophthalmol, 2017, 32(1): 67-74. doi: 10.1080/08820538.2016.1228397
[11]	Abdelrahman A, Massoud W, Elshafei AMK, et al. Anatomical and functional outcomes of subthreshold micropulse laser versus intravitreal ranibizumab injection in treatment of diabetic macular edema[J]. Int J Retina Vitreous, 2020, 6(1): 63. doi:10.1186/s40942-020-00265-6
[12]	Akhlaghi M, Dehghani A, Pourmohammadi R, et al. Effects of subthreshold diode micropulse laser photocoagulation on treating patients with refractory diabetic macular edema[J]. J Curr Ophthalmol, 2018, 31(2): 157-160. doi:10.1016/j.joco.2018.11.006
[13]	Li ZY, Song YP, Chen X, et al. Biological modulation of mouse RPE cells in response to subthreshold diode micropulse laser treatment[J]. Cell Biochem Biophys, 2015, 73(2): 545-552. doi:10.1007/s12013-015-0675-8
[14]	Takashina H, Watanabe A, Komatsu K, et al. Factors influencing threshold energy in subthreshold photocoagulation for diabetic macular edema[J]. Clin Ophthalmol, 2021, 15: 1827-1830. doi:10.2147/OPTH.S309828
[15]	刘洪新. 雷珠单抗联合阈值下微脉冲激光光凝治疗糖尿病视网膜病变患者的效果[J]. 中国民康医学, 2021, 33(17): 1-3. doi:10.3969/j.issn.1672-0369.2021.17.001 LIU Hongxin. Effects of Ranibizumab combined with subthreshold micropulse laser photocoagulation on patients with diabetic retinopathy[J]. Medical Journal of Chinese People's Health, 2021, 33(17): 1-3. doi:10.3969/j.issn.1672-0369.2021.17.001
[16]	吴琼, 王岩, 焦洁. 雷珠单抗注射液联合577 nm阈值下微脉冲激光光凝对糖尿病黄斑水肿患者CMT及TMV的影响[J]. 中国激光医学杂志, 2021, 30(3): 155-160. doi:10.13480/j.issn1003-9430.2021.0155 WU Qiong, WANG Yan, JIAO Jie. Effect of ranibizumab injection combined and 577nm micropulse laser photocoagulation on CMT and TMV of patients with diabetic macular edema[J]. Chinese Journal of Laser Medicine & Surgery, 2021, 30(3): 155-160. doi:10.13480/j.issn1003-9430.2021.0155
[17]	陈珊娜, 杨鹏飞, 陈松, 等. 亚阈值微脉冲黄激光联合雷珠单抗治疗糖尿病性黄斑水肿[J]. 国际眼科杂志, 2020, 20(4): 607-612. doi:10.3980/j.issn.1672-5123.2020.4.06 CHEN Shanna, YANG Pengfei, CHEN Song, et al. Comparison of single subthreshold micropulse yellow laser and combined with Ranibizumab intravitreal injection for diabetic macular edema[J]. International Eye Science, 2020, 20(4): 607-612. doi:10.3980/j.issn.1672-5123.2020.4.06
[18]	方立建, 魏文斌. 康柏西普玻璃体腔内注射联合阈值下微脉冲激光治疗糖尿病黄斑水肿的临床研究[J]. 中华眼科医学杂志(电子版), 2020, 10(2): 90-96. doi:10.3877/cma.j.issn.2095-2007.2020.02.005 FANG Lijian, WEI Wenbin. The effect of conbercept combined with subthreshold micropulse laser photocoagulation on diabetic macular edema[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2020, 10(2): 90-96. doi:10.3877/cma.j.issn.2095-2007.2020.02.005
[19]	Cusick M, Chew EY, Chan CC, et al. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels[J]. Ophthalmology, 2003, 110(11): 2126-2133. doi:10.1016/j.ophtha.2003.01.001
[20]	Otani T, Kishi S. Tomographic findings of foveal hard exudates in diabetic macular edema[J]. Am J Ophthalmol, 2001, 131(1): 50-54. doi:10.1016/s0002-9394(00)00661-9
[21]	雷家颖, 赵晓楠, 尹世达, 等. 抗VEGF联合激光光凝治疗老年糖尿病性黄斑水肿效果观察[J]. 老年医学研究, 2021, 2(4): 1-4. doi:10.3969/j.issn.2096-9058.2021.04.001 LEI Jiaying, ZHAO Xiaonan, YIN Shida, et al. Effect of anti-VEGF combined with laser photocoagulation on diabetic macular edema in elderly[J]. Geriatrics Research, 2021, 2(4): 1-4. doi:10.3969/j.issn.2096-9058.2021.04.001
[22]	Moisseiev E, Abbassi S, Thinda S, et al. Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema[J]. Eur J Ophthalmol, 2018, 28(1): 68-73. doi:10.5301/ejo.5001000
[23]	唐慧新, 李景景, 邹红. 阈值下微脉冲激光光凝作用机制及临床应用[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 143-148. doi:10.6040/j.issn.1673-3770.0.2022.254 TANG Huixin, LI Jingjing, ZOU Hong. Mechanism and clinical applications of subthreshold diode micropulse laser[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(3): 143-148. doi:10.6040/j.issn.1673-3770.0.2022.254
[24]	杭帆, 谭薇, 黄智华. 577 nm阈值下微脉冲激光与传统激光治疗DME疗效的系统评价[J]. 国际眼科杂志, 2020, 20(6): 1011-1015. doi:10.3980/j.issn.1672-5123.2020.6.19 HANG Fan, TAN Wei, HUANG Zhihua. A systematic evaluation of the efficacy differences of 577 nm subthreshold micropulse diode laser and conventional laser in the treatment of DME[J]. International Eye Science, 2020, 20(6): 1011-1015. doi:10.3980/j.issn.1672-5123.2020.6.19

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed